| Jeremy Smitherman, MD | |
|
1325 E Fortification St, Jackson, MS 39202-2442 | |
| (601) 354-4488 | |
| Not Available |
| Full Name | Jeremy Smitherman |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 16 Years |
| Location | 1325 E Fortification St, Jackson, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457507055 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 21996 (Mississippi) | Primary |
| 207L00000X | Anesthesiology | T2111 (Mississippi) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mississippi Baptist Medical Center | Jackson, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mississippi Sports Medicine And Orthopaedic Center | 4981685310 | 65 |
News Archive
A disciplinary hearing due to begin this week in the UK may well settle the debate over any link between the measles, mumps and rubella vaccine (MMR) and autism.
If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
› Verified 6 days ago
| Entity Name | Mississippi Sports Medicine & Orthopaedic Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415560 PECOS PAC ID: 4981685310 Enrollment ID: O20040601000238 |
News Archive
A disciplinary hearing due to begin this week in the UK may well settle the debate over any link between the measles, mumps and rubella vaccine (MMR) and autism.
If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
› Verified 6 days ago
| Entity Name | Jackson Anesthesia Pain Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104166362 PECOS PAC ID: 9638314867 Enrollment ID: O20130318000280 |
News Archive
A disciplinary hearing due to begin this week in the UK may well settle the debate over any link between the measles, mumps and rubella vaccine (MMR) and autism.
If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy Smitherman, MD 1325 E Fortification St, Jackson, MS 39202-2442 Ph: (601) 354-4488 | Jeremy Smitherman, MD 1325 E Fortification St, Jackson, MS 39202-2442 Ph: (601) 354-4488 |
News Archive
A disciplinary hearing due to begin this week in the UK may well settle the debate over any link between the measles, mumps and rubella vaccine (MMR) and autism.
If you think vaccination is an ordeal now, consider the 18th-century version. After having pus from a smallpox boil scratched into your arm, you would be subject to three weeks of fever, sweats, chills, bleeding and purging with dangerous medicines, accompanied by hymns, prayers and hell-fire sermons by dour preachers.
Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
› Verified 6 days ago